
Aberdeen's healthcare fund outperforms as uniQure shares surge on FDA gene therapy approval news
Aberdeen Asset Management's Healthcare Opportunities Fund equity portion gained and outperformed its benchmark, driven by uniQure's strong share price rise after the FDA accepted its AMT-130 gene therapy data for accelerated approval in Huntington's ...
